anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) represents a frequent complication of in critically ill patients. The objective of this study is to illuminate the potential protective activity of Micheliolide (MCL) and its behind mechanism against SA-AKI.
METHODS: The protective potential of MCL on SA-AKI was investigated in lipopolysaccharide (LPS) treated HK2 cells and SA-AKI mice model. The mitochondrial damage was determined by detection of reactive oxygen species and membrane potential. The Nrf2 silencing was achieved by transfection of Nrf2-shRNA in HK2 cells, and Nrf2 inhibitor, ML385 was employed in SA-AKI mice. The mechanism of MCL against SA-AKI was evaluated through detecting hallmarks related to inflammation, mitophagy and Nrf2 pathway via western blotting, immunohistochemistry, and enzyme linked immunosorbent assay.
RESULTS: MCL enhanced viability, suppressed apoptosis, decreased inflammatory cytokine levels and improved mitochondrial damage in LPS-treated HK2 cells, and ameliorated renal injury in SA-AKI mice. Moreover, MCL could reduce the activation of NLRP3 inflammasome via enhancing mitophagy. Additionally, Nrf2 deficiency reduced the suppression effect of MCL on NLRP3 inflammasome activation and blocked the facilitation effect of MCL on mitophagy in LPS-treated HK2 cells, the consistent is true for ML385 treatment in SA-AKI mice.
CONCLUSIONS: MCL might target Nrf2 and further reduce the NLRP3 inflammasome activation via enhancing mitophagy, which alleviated SA-AKI.
Camel Snus (oral smokeless tobacco product). Dosage: 1.74-1.97 mg nicotine per portion.
The BMI predicts mortality and cardiovascular disease (CVD) in the general population, while in patients with end-stage chronic kidney disease (CKD) a high BMI is associated with improved survival, a phenomenon referred to as the "obesity paradox". While BMI is easy to determine and helps to categorize patients, it does not differentiate between fat tissue, lean tissue and bone mass. As the BMI may be altered in CKD, e.g. by muscle wasting, we determined in this meta-analysis (i) the association of mortality with fat tissue quantity in CKD and (ii) the association of mortality with abdominal obesity (as measured by waist circumference (WC) or waist-to-hip ratio (WHR)) in CKD. We systematically reviewed databases for prospective or retrospective cohort studies. In eleven studies with 23,523 patients the association between mortality and high fat tissue quantity in CKD was calculated. The pooled hazard ratio (HR) for this association in the CKD group in the dialysis group 0.91 (CI 0.84- 0.98, p = 0.01) which is comparable to the HR for the association with BMI. The HR in patients without dialysis was 0.7 (95% CI 0.53- 0.93, p = 0.01), suggesting a better risk prediction of high fat tissue content with mortality as compared to higher BMI with mortality in patients with CKD without dialysis. Importantly, both BMI and fat tissue quantity in CKD are described by the "obesity paradox": the higher the fat tissue content or BMI, the lower the mortality risk. In thirteen studies with 55,175 patients the association between mortality and high WC or WHR in CKD (with or without dialysis) was calculated. We observed, that the HR in the WHR group was 1.31 (CI 1.08-1.58, p = 0.007), whereas the overall hazard ratio of both groups was 1.09 (CI 1.01-1.18, p = 0.03), indicating that a higher abdominal obesity as measured by WHR is associated with higher mortality in CKD. Our analysis suggests gender-specific differences, which need larger study numbers for validation. This meta-analysis confirms the obesity paradox in CKD using fat tissue quantity as measure and further shows that using abdominal obesity measurements in the routine in obese CKD patients might allow better risk assessment than using BMI or fat tissue quantity. Comparable to the overall population, here, the higher the WHR, the higher the mortality risk.
A scleral prosthesis includes an elongated body having a first free end, a second free end opposite the first free end, a central portion extending between and coupling the ends, and a convex top surface extending lengthwise along at least part of the central portion. A maximum width of the body at each end is wider than a maximum width of the body along the central portion. The scleral prosthesis also includes an insert having a convex top surface extending lengthwise along at least part of the insert. The body includes multiple portions that form the first end and part of the central portion. The portions are separated lengthwise along part of a total length of the body by empty space, which tapers and then expands in width. The insert has a shape complementary to the empty space such that the insert tapers and then expands in width.
This patients will be submitted to the standard surgery protocol in the institution. The patients will not be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion.
Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, saline \[Kcentra saline control or TXA saline control\] on Day 4 in Part 2.
1,235,529. Mucolytic compositions. CALIBIOCHEM. 2 Dec., 1968, No. 57019/68. Heading A5B. A medicament for the liquefaction of mucous accumulations in human beings comprises a pharmaceutically acceptable carrier containing 1,4-dimercapto 2,3-dihydroxybutane in amount equal to 0.016‹ to 2.0% by weight of the carrier. The medicament may be administered orally in the form of gelatin capsules or by inhalation of a powder, a spray solution from an atomizer or nebulizer, a solution or powder from an aerosol. The 1,4-dimercapto-2,3-dihydroxybutane may be present as any of its stereo isomers or mixtures thereof. The medicament may be adjusted to a pH of 7.0 or less. The medicament may also contain ephedrine sulphate, chlorcyclizine and chlorobutanol.
In response to intraoperative stress, increased autonomic sympathetic activity may alter myocardial oxygen demand. Under normal physiological circumstances, sympathetic stimulation increases myocardial blood flow via adrenergic coronary vasodilation. However, coronary vessels contain both α- and β-adrenoreceptors, and if the coronary circulation is impaired due to cardiovascular disease, unopposed adrenergic coronary vasoconstriction may contribute to ischemia. Anesthetics reduce both coronary blood flow (CBF) regulation and the sympathetic autonomic nervous activity. However, it is unclear whether anesthetic-related reductions in CBF are a result of inhibited autonomic sympathetic innervation. Data regarding alterations in myocardial blood flow in response to sympathetic stimulation during anesthesia provide conflicting results. Moffitt and Sethna showed in patients undergoing cardiac surgery that CBF decreased during sternotomy-induced sympathetic stimulation, whereas Kirno et al. showed an increase in coronary blood flow after sternotomy. To our best knowledge, coronary vascular responses to sympathetic stimulation in anesthetized healthy humans are lacking because of absence of reliable non-invasive measurement of myocardial blood flow. The introduction of non-invasive contrast-echocardiographic techniques that allow evaluation of regional myocardial blood flow enable evaluation of the relation between autonomic control and CBF during anesthesia.

Cardiac complications like myocardial ischemia remain one of the main causes of perioperative morbidity and mortality. Interestingly, the presence of cardiovascular autonomic neuropathy (CAN) strongly predicts abnormalities in myocardial perfusion and impaired coronary vasodilator responses to stress. This implies that symptoms of CAN, like resting tachycardia, orthostasis and alterations in heart rate variability may predict the degree of impairment of CBF regulation. Indeed, autonomic neuropathy as determined by heart rate variability predicted mortality in patients with coronary artery disease undergoing non-cardiac surgery, but the contribution of impaired coronary vasodilatory responses to these results has not been established. Clarification of the relation between autonomic control and CBF during anesthesia may not only contribute to our insight in pro-ischemic processes in the heart, but may lead to changes in preoperative assessment of patients at risk for perioperative ischemia, thereby reducing perioperative complications.
CMV Retinitis: Patients should be advised that FOSCAVIR is not a cure for CMV retinitis, and that they may continue to experience progression of retinitis during or following treatment. They should be advised to have regular ophthalmologic examinations. 

Mucocutaneous Acyclovir-Resistant HSV Infections: Patients should be advised that FOSCAVIR is not a cure for HSV infections. While complete healing is possible, relapse occurs in most patients. Because relapse may be due to acyclovir-sensitive HSV, sensitivity testing of the viral isolate is advised. In addition, repeated treatment with FOSCAVIR has led to the development of resistance associated with poorer response. In the case of poor therapeutic response, sensitivity testing of the viral isolate also is advised. 

Effects on Ability to Drive and Use Machines: Adverse effects such as dizziness and convulsions may occur during FOSCAVIR therapy. Patients who experience seizures, dizziness, somnolence or other adverse reactions that could result in impairment, should be advised to avoid driving or operating machinery.

General: Patients should be informed that the major toxicities of foscarnet are renal impairment, electrolyte disturbances, and seizures, and that dose modifications and possibly discontinuation may be required. The importance of close monitoring while on therapy must be emphasized. Patients should be advised of the importance of reporting to their physicians symptoms of perioral tingling, numbness in the extremities or paresthesias during or after infusion as possible symptoms of electrolyte abnormalities. Patients should also be advised to promptly report any cardiac symptoms. Should such symptoms occur, the infusion of FOSCAVIR should be stopped, appropriate laboratory samples for assessment of electrolyte concentrations obtained, and a physician consulted before resuming treatment. The rate of infusion must be no more than 1 mg/kg/minute. The potential for renal impairment may be minimized by accompanying FOSCAVIR administration with hydration adequate to establish and maintain a diuresis during dosing.
The results from the KRAM Study are used as baseline for this intervention. In the KRAM study all adult citizens (18+ years) in 13 Danish municipalities were invited by letter to take part in an internet based questionnaire concerning socio-demography, life style, and other health aspects. Furthermore, a random sample of the citizens was invited to participate in a health examination. A total of 76.484 of the invited 538.497 citizens filled in the entire or partially the questionnaire and 18.065 of the invited 180.103 citizens completed the health examination. The examination included the following measurements: Blood pressure, height, weight, fat percentage, blood samples, pulmonary function, bone mineral density, muscle strength, balance test, and aerobic fitness.

Intervention The intervention was carried out in three of the 13 municipalities (Silkeborg, Frederiksberg, and Varde). Participants with a low aerobic fitness (defined for men and women in different age groups) or those who reported being sedentary or light physically active in leisure time were - after they had accomplished the health examination - invited to participate in the intervention. Participants were not included if they participated in other interventions initiated in relation with the KRAM Study or if they were pregnant. All participants gave informed consent. The protocol was approved by the Scientific Ethical Committee B for the Capital Region of Denmark (H-B-2008-097).

The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program, a handout with a summary of the pedometer program, and a calendar for registration of daily steps. The aim of the program is to guide people to use a pedometer and increase their steps with 20 % each week until they reach their goal. During the trial period, they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening, they should take the pedometer off and register the total number of steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program. Participants assigned to the control group received a leaflet from the National Board of Health in Denmark recommending all adults to be physical active for 30 minutes each day of moderate intensity.

Follow up After 12 weeks, participants were invited by letter to answer a short questionnaire. Furthermore, they were invited to participate in a health examination including the measurements of blood pressure, weight, fat percentage, and aerobic fitness. The researchers who performed the examinations were blinded to group assignment.
A process of preparing an active pharmaceutical ingredient salt, the process comprising the steps of: (i) forming a mixture comprising an active pharmaceutical ingredient, a salt forming substance and one or more solvents; (ii) contacting the mixture with a supercritical fluid to form a salt of the active pharmaceutical ingredient and the salt forming substance; and (iii) obtaining the active pharmaceutical ingredient salt. The preferred pharmaceutical ingredient is ketoconazole and the preferred salt is an oxalate. Preferably, the solvents are all organic solvents. The preferred supercritical fluids are supercritical carbon dioxide or supercritical nitrogen. Preferably, the pKa difference between the active pharmaceutical ingredient and the salt forming substance is 1 or more. More preferably, the active pharmaceutical ingredient is basic, the salt forming substance is an acid and the pKa difference between the basic active pharmaceutical ingredient and the acid is 1 or more. The present invention also relates to the active pharmaceutical ingredient salt obtained/obtainable from the above process. The present invention further relates to pharmaceutical compositions comprising said active pharmaceutical ingredient salt and to the use of such an active pharmaceutical ingredient salt in the treatment and prevention of medical disorders and diseases.
The invention discloses a formula of a cough-relieving medicament and a preparation method thereof. The medicament is composition solution prepared by procedures such as decoction, filtering, boiling and mixing of folium eriobotryae, pericarpium papaveris, radix stemonae, cynanchum glaucescens, the root bark of white mulberry, platycodon grandiflorum, menthol crystal, cane sugar, citric acid, essence, sodium benzoate, dextromethorphan hydrobromide, promethazine hydrochloride, 75% of alcoholic solution, distilled water and the like. The cough-relieving medicament can be suitable for curing cough caused by various respiratory incentives. After patients orally take the cough-relieving medicament, no body function allergic reaction occurs. The cough-relieving medicament has no toxic or side effect and can be rapidly absorbed and utilized by bodies. The cure purpose of relieving cough and asthma can be achieved by tonifying kidneys, strengthening spleens and moistening lungs. The cough-relieving medicament is low in cost, and the preparation process is simple, convenient and easy to implement.
PURPOSE:To obtain the subject pack effective in removing excess fat and waste product and giving smooth and moist skin by using shell fossil crushed to fine powder and compounding the shell fossil powder with water or a mixture of water and a seaweed component wherein the water may be replaced with a mineral water prepared by contacting shell fossil with water. CONSTITUTION:The objective packing agent for the beauty treatment of whole body contains (A) fine powder of shell fossil having an average particle size of 150-200mum and water or (B) fine powder of shell fossil having an average size of 150-200mum, a seaweed component and water wherein the water used in the above composition may be replaced with a mineral water prepared by contacting shell fossil with water. The shell fossil is rich in minerals such as Ca and Mg in the form of carbonates, hydroxides, etc., and has fat-absorbing property. It has heat-insulation property to increase the skin temperature by about 1 deg.C to promote the action of the ingredient component on the skin. The seaweed component has astringent effect and moisture-retaining effect to the skin. Moist and smooth skin can be attained by the use of the pack.
Components of evidence-based cognitive behavioral therapy (CBT) treatments from current manuals developed for depression and anxiety will be used to construct the 8-week treatment program. The flexibility of modular based treatment allows patients and counselors to personalize interventions and skills for managing anxiety and depressive symptoms. The first treatment session will be in-person. All following sessions will be provided by telephone. Caregivers will have the option of being involved in 2 ways throughout treatment - as a "coach" to facilitate use of new skills by their loved one with PD and as a recipient of stress- management support. The scope of caregiver involvement will vary across patients, based on their preference. Involved caregivers will be given the opportunity to participate in 1 telephone-based stress-management session and 1 follow-up call scheduled individually during the first 4 weeks of treatment.
ABSTRACT       Alcohol disorders have been treated with a variety of therapies, including pharmaceutical. Benzodiazepines, are one type of pharmaceutical that has aided in treating the anxiety associated with alcohol disorders, however there are serious risks of abuse and dependence. Disulfiram is another pharmaceutical that provides a deterrent against consuming alcohol since it causes a person to become very ill when combined with alcohol. The deterrent effect of disulfiram is only effective when taken and non-compliance is a major limitation. This invention relates to a combination pharmaceutical medicine of disulfiram and a benzodiazepine that acts in an agonist-aversive manner for people with alcohol disorders. The combination of disultiram and a benzodiazepine acts to reduce anxiety and deter alcohol consumption at the same time. This invention also relates to other combinations of agonist and aversive medicines to reduce anxiety and deter alcohol consumption. This invention also relates to aversive medicines combined with other agents to treat medical conditions, which medical conditions or agents' effectiveness are negatively impacted by the consumption of ethanol.
Cosmetic use of guanosine and/or its derivative to prevent an alteration of, and/or maintain the homeostasis of the skin, is claimed. Independent claims are included for: (1) the guanosine and/or its derivative in a dermatological composition for preventing and/or treating an inflammatory condition of the skin; (2) cosmetic and/or dermatological composition comprising, in a medium, at least an effective amount of a first active agent or compound, and a second active agent, where the first active agent or compound is capable or be deemed to perform irritant effect with respect to the skin, and the second active agent is guanosine for preventing and/or treating the irritant effect caused by the first active agent or compound; and (3) ensemble for simultaneous, separate or sequential use, comprising a first cosmetic composition and/or dermatological composition comprising, in a medium, at least an active agent, or compound capable of, or suspected, exert an irritating effect in respect of the skin, and second cosmetic and/or dermatological composition comprising, in a medium, the guanosine. ACTIVITY : Dermatological; Antiinflammatory; Vulnerary; Anabolic. MECHANISM OF ACTION : Hyaluronan synthase 3 stimulator. The ability of the guanosine to stimulate hyaluronan synthase 3 was tested in human epidermis. The result showed that the percentage of stimulation was 228%.
Right ventricular (RV) failure remains the strongest determinant of survival in pulmonary hypertension (PH). We aimed to identify relevant mechanisms, beyond pressure overload, associated with maladaptive RV hypertrophy in PH. To separate the effect of pressure overload from other potential mechanisms, we developed in pigs two experimental models of PH (M1, by pulmonary vein banding and M2, by aorto-pulmonary shunting) and compared them with a model of pure pressure overload (M3, pulmonary artery banding) and a sham-operated group. Animals were assessed at 1 and 8 months by right heart catheterization, cardiac magnetic resonance and blood sampling, and myocardial tissue was analyzed. Plasma unbiased proteomic and metabolomic data were compared among groups and integrated by an interaction network analysis. A total of 33 pigs completed follow-up (M1, n = 8; M2, n = 6; M3, n = 10; and M0, n = 9). M1 and M2 animals developed PH and reduced RV systolic function, whereas animals in M3 showed increased RV systolic pressure but maintained normal function. Significant plasma arginine and histidine deficiency and complement system activation were observed in both PH models (M1&M2), with additional alterations to taurine and purine pathways in M2. Changes in lipid metabolism were very remarkable, particularly the elevation of free fatty acids in M2. In the integrative analysis, arginine-histidine-purines deficiency, complement activation, and fatty acid accumulation were significantly associated with maladaptive RV hypertrophy. Our study integrating imaging and omics in large-animal experimental models demonstrates that, beyond pressure overload, metabolic alterations play a relevant role in RV dysfunction in PH.
CircRNAs are involved in multiple aspects during carcinogenesis, including tumorigenesis, vascularization, apoptosis and others. Exploring the role of circRNAs in breast cancer (BC) enables us to understand the development mechanism of BC more comprehensively. Here, we screened out and verified an up-regulated circRNA in BC from GEO data. Quantitative Real-time PCR (qRT-PCR) showed that circ_0065214 had a high expression level in BC patients. Besides, circ_0065214 had good diagnostic value in BC serum, and the area under the diagnostic curve, sensitivity and specificity were 0.78, 0.63 and 0.85, respectively. The combined application of circ_0065214 with CEA and CA-153 can further improve the diagnostic efficiency. The knockdown of circ_0065214 in vivo and in vitro inhibited the proliferation, migration and invasion of BC, but promoted autophagy. At last, dual-luciferase reporter assay and rescue assays revealed that circ_0065214 acted as a decoy to adsorb miR-188-3p, and then relieved the repressive effect of miR-188-3p on its target GPNMB. Our results demonstrated that circ_0065214 regulated the expression of GPNMB by competitively binding to miR-188-3p, thus promoting the proliferation, migration and invasion of breast cancer cells and inhibiting autophagy. These findings provided an original therapeutic strategy for BC.